These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Local nasal immunotherapy: efficacy and tolerability of two different administration schedules in grass pollen rhinitis. Senna GE; Andri G; Dama AR; Falagiani P; Andri L Allergol Immunopathol (Madr); 2000; 28(4):238-42. PubMed ID: 11022271 [TBL] [Abstract][Full Text] [Related]
63. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808 [TBL] [Abstract][Full Text] [Related]
64. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma. Rossi RE; Monasterolo G Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250 [TBL] [Abstract][Full Text] [Related]
68. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health. Rose K; Kopp MV Pediatr Allergy Immunol; 2015 Dec; 26(8):695-701. PubMed ID: 26495999 [TBL] [Abstract][Full Text] [Related]
69. Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma: A systematic review and meta-analysis. Jiang Z; Xiao H; Zhang H; Liu S; Meng J Am J Otolaryngol; 2019; 40(6):102269. PubMed ID: 31422860 [TBL] [Abstract][Full Text] [Related]
70. Gaps in allergen immunotherapy administration and subcutaneous allergen immunotherapy dose adjustment schedules: Need for prospective data. Larenas-Linnemann DE; Epstein T; Ponda P; Bernstein D; Williams P; Creticos P Ann Allergy Asthma Immunol; 2020 Nov; 125(5):505-506.e2. PubMed ID: 32693206 [No Abstract] [Full Text] [Related]
71. Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. Pfaar O; Angier E; Muraro A; Halken S; Roberts G Allergy; 2020 Sep; 75(9):2411-2414. PubMed ID: 32163594 [No Abstract] [Full Text] [Related]
72. Recent developments and highlights in rhinitis and allergen immunotherapy. Reitsma S; Subramaniam S; Fokkens WWJ; Wang Y Allergy; 2018 Dec; 73(12):2306-2313. PubMed ID: 30260494 [TBL] [Abstract][Full Text] [Related]
73. Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients. Barth C; Anero F; Pfaar O; Klimek L; Hörmann K; Stuck BA Eur Arch Otorhinolaryngol; 2010 Dec; 267(12):1873-9. PubMed ID: 20454971 [TBL] [Abstract][Full Text] [Related]
78. Compounding a Problem? Berlin J Tex Med; 2016 May; 112(5):63-9. PubMed ID: 27175928 [TBL] [Abstract][Full Text] [Related]
79. [Immunologic control parameters during specific immunotherapy]. Ott H; Wosnitza M; Merk HF Hautarzt; 2008 Jul; 59(7):551-6. PubMed ID: 18553185 [TBL] [Abstract][Full Text] [Related]